Microsatellite Instability Testing
The latest news on microsatellite instability testing.
BMS's Opdivo-Yervoy Combo Approved in Europe for First-Line Treatment of Certain Colorectal Cancers
The drug combo is the first dual checkpoint inhibitor therapy approved in Europe for first-line metastatic MSI-H or dMMR colorectal cancer.
Ideaya Biosciences to Develop KAT6/7 Inhibitor in 8p11-Amplified Breast, Lung Cancers
The firm plans to file an investigational new drug application to study IDE251 in clinical trials in 2025.
Accent Therapeutics Treats First Patient in Phase I DHX9 Inhibitor Trial
The study is designed to evaluate the safety, tolerability, and preliminary efficacy of ATX-559 in certain biomarker-selected cancer patients.
EMA's CHMP Recommends Approval for First-Line Opdivo-Yervoy in Certain Colorectal Cancers
Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.
Marengo Therapeutics Advancing Bispecific Antibody to Phase II After Positive First-in-Human Data
Premium
A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.